Varian Medical’s latest ProBeam wins CE Mark

Varian Medical (NYSE:VAR) said it won CE Mark approval in the European Union for its latest generation ProBeam proton therapy system.

Proton therapy is designed for precise treatment of certain types of cancer while providing potentially fewer side effects than conventional radiation therapy, the Palo Alto, Calif.-based company said.

In addition to precision, proton therapy reduces the risk of damage to healthy tissue due to controlled proton beams that can be targeted directly to the tumor site and avoid passing through the patient, Varian said.

The new version of the ProBeam is capable of high-speed intensity modulated proton therapy, the most precise proton therapy available, the company said.

Last week, Varian said it won FDA 510(k) clearance and CE Mark approval in the European Union for its VitalBeam radiotherapy system.

The VitalBeam system is a modular, high-throughput radiotherapy system which incorporates technology from the company’s TrueBeam radiotherapy system, the company said.

In July, Varian Medical released its fiscal Q3 earnings and announced it acquired Netherlands-based X-ray component manufacturer Claymount for $55 million (€50 million).

The company grew from Q3 last year but failed to meet the street on earnings and revenue. Varian reported $1.13 earnings per share for the quarter, an 11¢ increase since last year, but still 10¢ below analysts expectations.

The post Varian Medical’s latest ProBeam wins CE Mark appeared first on MassDevice.

from MassDevice http://ift.tt/1N9AFf4